Novartis's Bexsero Receives FDA Breakthrough Therapy Designation - - BioPharm International


Novartis's Bexsero Receives FDA Breakthrough Therapy Designation

Novartis reported that Bexsero has received a breakthrough therapy designation from FDA. Bexsero is already approved in Europe, Canada, and Australia to help protect against meningococcal disease caused by serogroup B (meningitis B).

This announcement comes after a decision from regulators in the UK, where the Joint Committee on Vaccination and Immunization recommended the inclusion of Bexsero in the country's National Immunization Program forroutine use in infants two years and up.

Source: Novartis
blog comments powered by Disqus



Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines

Click here